Patheon Pharmaceuticals Seeks DEA Approval for Bulk Manufacturing of Controlled Substance
March 13, 2025
March 13, 2025
WASHINGTON, March 13 (TNSFR) -- Patheon Pharmaceuticals Inc., a pharmaceutical company headquartered in Cincinnati, Ohio, has applied to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of Gamma Hydroxybutyric Acid (GHB), a Schedule I controlled substance. The company seeks authorization to produce GHB as an Active Pharmaceutical Ingredient (API), which will then be further synthesized into FDA-approved dosage forms.
As a Schedule I substance, GHB i . . .
As a Schedule I substance, GHB i . . .